Rare Side Effects of Stimulants: Raynaud’s Phenomenon

References (16)

1. American Academy of Child & Adolescent Psychiatry. ADHD Parents Medication Guide. July 2013. American Psychiatric Association. Accessed August 11, 2021. https://www.psychiatry.org/File%20Library/Psychiatrists/Practice/Professional-Topics/Child-Adolescent-Psychiatry/adhd-parents-medication-guide.pdf
2. Prescription Drug Use in the United States. 2015-2016. NCHS Data Brief No. 334. Centers for Disease Control and Prevention. May 2019. Accessed August 11, 2021. https://www.cdc.gov/nchs/products/databriefs/db334.htm
3. Gnanavel S. Lisdexamfetamine and secondary Raynaud’s phenomenon. Prim Care Companion CNS Disord. 2018;20(5):17l02240. PubMed CrossRef
4. Bayram Ö, Hergüner S. OROS-methylphenidate-induced Raynaud’s phenomenon: a dose-related side effect. J Child Adolesc Psychopharmacol. 2015;25(6):521–522. PubMed CrossRef
5. Syed RH, Moore TL. Methylphenidate and dextroamphetamine-induced peripheral vasculopathy. J Clin Rheumatol. 2008;14(1):30–33. PubMed CrossRef
6. Goldman W, Seltzer R, Reuman P. Association between treatment with central nervous system stimulants and Raynaud’s syndrome in children: a retrospective case-control study of rheumatology patients. Arthritis Rheum. 2008;58(2):563–566. PubMed CrossRef
7. Al Aboud A, Abrams M, Mancini AJ. Blue toes after stimulant therapy for pediatric attention deficit hyperactivity disorder. J Am Acad Dermatol. 2011;64(6):1218–1219. PubMed CrossRef
8. Yu ZJ, Parker-Kotler C, Tran K, et al. Peripheral vasculopathy associated with psychostimulant treatment in children with attention-deficit/hyperactivity disorder. Curr Psychiatry Rep. 2010;12(2):111–115. PubMed CrossRef
9. Khouri C, Blaise S, Carpentier P, et al. Drug-induced Raynaud’s phenomenon: beyond β-adrenoceptor blockers. Br J Clin Pharmacol. 2016;82(1):6–16. PubMed CrossRef
10. Iglesias Otero M, Portela Romero M, Bugarín González R, et al. Methylphenidate and secondary Raynaud’s phenomenon [in Spanish]. Semergen. 2013;39(6):330–334. PubMed CrossRef
11. Arnold LE. Methyiphenidate vs amphetamine: comparative review. J Atten Disord. 2000;3(4):200–211. CrossRef
12. Goodwin JS, Larson GA, Swant J, et al. Amphetamine and methamphetamine differentially affect dopamine transporters in vitro and in vivo. J Biol Chem. 2009;284(5):2978–2989. PubMed CrossRef
13. Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines—the diagnosis and management of Raynaud’s phenomenon. Vasa. 2017;46(6):413–423. PubMed CrossRef
14. Meridor K, Levy Y. Systemic sclerosis induced by CNS stimulants for ADHD: a case series and review of the literature. Autoimmun Rev. 2020;19(1):102439. PubMed CrossRef
15. Monteerarat Y, Pariwatcharakul P. Methylphenidate-induced Raynaud phenomenon developed after increasing methylphenidate in an adult with attention-deficit hyperactivity disorder. J Clin Psychopharmacol. 2019;39(2):178–179. PubMed CrossRef
16. Tan G, Mintz AJ, Mintz B, et al. Peripheral vascular manifestation in patients receiving an amphetamine analog: a case series. Vasc Med. 2019;24(1):50–55. PubMed CrossRef